



SPAFID  
CONNECT

Informazione Regolamentata n. 0472-8-2021	Data/Ora Ricezione 19 Febbraio 2021 09:07:34	MTA - Star
---	--	------------

Societa' : BB BIOTECH  
Identificativo : 142635  
Informazione  
Regolamentata  
Nome utilizzatore : BIOTECHNSS01 - Alderuccio  
Tipologia : 1.1  
Data/Ora Ricezione : 19 Febbraio 2021 09:07:34  
Data/Ora Inizio : 19 Febbraio 2021 09:07:35  
Diffusione presunta  
Oggetto : BB Biotech AG publishes its 2020 annual  
report

*Testo del comunicato*

Vedi allegato.

Media release as of February 19, 2021

Annual report of BB Biotech AG as of December 31, 2020

## **BB Biotech AG publishes its 2020 annual report**

BB Biotech AG published its annual report for fiscal year 2020 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the investment areas covered by its portfolio and the companies it is invested in.

BB Biotech performed well in a volatile market environment. For the full year, total share return was 19.3% in CHF and 18.1% in EUR and the portfolio performance was 24.3% in CHF, and 24.8% in EUR. The consolidated and audited full year 2020 data showed a net gain of CHF 691 mn compared to a net gain of CHF 677 mn for 2019.

As already announced on January 22, 2021, BB Biotech will propose a dividend of CHF 3.60 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2020. This marks a continuation of the dividend policy of the previous years.

BB Biotech's annual report 2020 is available under [report.bbbiotech.ch/2020/en](https://report.bbbiotech.ch/2020/en) resp. [www.bbbiotech.com](https://www.bbbiotech.com).

### **For further information:**

#### **Investor Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Dr. Silvia Siegfried-Schanz, [ssc@bellevue.ch](mailto:ssc@bellevue.ch)

Maria-Grazia Iten-Alderuccio, [mga@bellevue.ch](mailto:mga@bellevue.ch)

Claude Mikkelsen, [cmi@bellevue.ch](mailto:cmi@bellevue.ch)

#### **Media Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Tanja Chicherio, [tch@bellevue.ch](mailto:tch@bellevue.ch)

TE Communications AG, St. Leonhard-Strasse 45, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28

Thomas Egger, [teg@te-communications.ch](mailto:teg@te-communications.ch)

**[www.bbbiotech.com](https://www.bbbiotech.com)**

#### **Company profile**

BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.

Fine Comunicato n.0472-8

Numero di Pagine: 3